Skip to main content

Table 5 24-h urinary glucose and electrolyte excretion, after single-dose administration of remogliflozin etabonate (20–1000 mg) in healthy volunteers (n = 8 per remogliflozin etabonate group and n = 10 for placebo) and subjects with T2DM (n = 6)

From: First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

Parameter Placebo Remogliflozin etabonate dose, mg
20 50 150 500 1000
Healthy subjects
Urinary glucose excretion (mmol) 6.5 (18.6)a 67.1 (17.9) 96.7 (17.1)b 168 (49.4)b 223 (49.5) 304 (137)
Filtered glucose excreted in urine (%) 0.9 (2.4)a 9.0 (2.2) 12.7 (3.7)b 25.5 (7.8)b 34.2 (5.0) 26.4 (11.7)
Urinary sodium excretion (mmol) 162 (49.4)a 148 (64.0) 212 (67.6)b 176 (38.7)b 143 (55.0) 207 (62.9)
Urinary chloride excretion (mmol) 141 (39.8)a 136 (56.6) 189 (51.4)b 179 (49.6)b 126 (55) 201 (61.5)
Urinary potassium excretion (mmol) 62.2 (15.7)a 66.6 (27.7) 75.2 (21.3)b 59.7 (20.3)b 55.8 (17.2) 89.1 (24.7)
T2DM subjects
Urinary glucose excretion (mmol) 40.4 (62.4)c   384 (210)   642 (256)  
Filtered glucose excreted in urine (%) 2.3 (3.6)c   15.9 (5.9)c   21.6 (9.1)  
Urinary sodium excretion (mmol) 196 (39.2)c   173 (35.5)c   301 (128)  
Urinary chloride excretion (mmol) 181 (48.3)c   168 (23.9)c   287 (147)  
Urinary potassium excretion (mmol) 71.7 (12.1)c   65.8 (4.5)c   108 (65.8)  
  1. Results are expressed as mean (SD).
  2. a. n = 9.
  3. b. n = 7.
  4. c. n = 5.